Xiaoqiang Li

Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1

Hui Li, Xiaoqiang Li, Shuang Liu et al. · Hepatology · 2017 · 200 citations

Medicine, Oncology, Pharmacology +17

MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1

Hui Li, Chia‐Wei Li, Xiaoqiang Li et al. · Gastroenterology · 2019 · 187 citations · Full text

Medicine, Immunology, Oncology +12

Spot-Scanning Proton Arc (SPArc) Therapy: The First Robust and Delivery-Efficient Spot-Scanning Proton Arc Therapy

Xuanfeng Ding, Xiaoqiang Li, J Michele Zhang et al. · International Journal of Radiation Oncology*Biology*Physics · 2016 · 161 citations

Medicine, Oncology, Radiation Oncology +12

Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis

Liusheng Wu, Yanfeng Zhong, Dingwang Wu et al. · Biomedicines · 2022 · 121 citations · Full text

Medicine, Biostatistics, Oncology +17

Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research

Liusheng Wu, Yanfeng Zhong, Xiaoya Yu et al. · Anti-Cancer Drugs · 2022 · 120 citations · Full text

Medicine, Immunology, Oncology +17